Department of Radiology, Johns Hopkins University, Baltimore, Maryland;
Department of Radiology, University of Michigan, Ann Arbor, Michigan.
J Nucl Med. 2021 Dec;62(Suppl 3):12S-22S. doi: 10.2967/jnumed.121.262750.
Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.
放射性药物治疗 (RPT) 被定义为将放射性原子递送到肿瘤相关靶标。在 RPT 中，由于 RPT 中使用的放射性核素通常会发射光子或可以使用替代物进行成像，因此成像被构建到治疗模式中。这种成像可用于估计肿瘤吸收剂量。我们检查并试图阐明影响 RPT 药物吸收剂量-反应关系的因素。这些因素包括炎症或免疫介导作用的作用、治疗诊断成像的意义、放射生物学、不同患者之间的剂量学方法差异、药代动力学差异以及肿瘤缺氧对 RPT 反应的影响。
